Loading...

We've got a brand new version of Simply Wall St! Try it out

TaiMed Biologics

GTSM:4147
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4147
GTSM
NT$35B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

TaiMed Biologics Inc., a biotechnology company, develops health-care products. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
4147 Share Price and Events
7 Day Returns
-1.8%
GTSM:4147
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
-11.9%
GTSM:4147
-9.6%
TW Biotechs
17.7%
TW Market
4147 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TaiMed Biologics (4147) -1.8% -3.5% -3.2% -11.9% -21.9% -1.5%
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 4147 underperformed the Biotechs industry which returned -9.6% over the past year.
  • 4147 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4147
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for TaiMed Biologics's competitors could be found in our database.

Value

 Is TaiMed Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of TaiMed Biologics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for TaiMed Biologics.

GTSM:4147 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in TWD NT$ 1.0175066666667
Payout Ratio Company Filings (2019-09-30) 0%
Discount Rate (Cost of Equity) See below 11%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4147
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 20%) (0.1%))
1.391
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.391 * 5.96%)
11.02%

Discounted Cash Flow Calculation for GTSM:4147 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for TaiMed Biologics is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:4147 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$1.02 / (11.02% - 2.73%)
NT$12.27
GTSM:4147 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$12.27
Current discount Discount to share price of NT$137.50
= -1 x (NT$137.50 - NT$12.27) / NT$12.27
-1020.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of TaiMed Biologics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TaiMed Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TaiMed Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4147 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$-2.59
GTSM:4147 Share Price ** GTSM (2019-11-11) in TWD NT$137.5
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TaiMed Biologics.

GTSM:4147 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4147 Share Price ÷ EPS (both in TWD)

= 137.5 ÷ -2.59

-53.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TaiMed Biologics is loss making, we can't compare its value to the TW Biotechs industry average.
  • TaiMed Biologics is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does TaiMed Biologics's expected growth come at a high price?
Raw Data
GTSM:4147 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -53.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
127%per year
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TaiMed Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TaiMed Biologics's assets?
Raw Data
GTSM:4147 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$14.52
GTSM:4147 Share Price * GTSM (2019-11-11) in TWD NT$137.5
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:4147 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4147 Share Price ÷ Book Value per Share (both in TWD)

= 137.5 ÷ 14.52

9.47x

* Primary Listing of TaiMed Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TaiMed Biologics is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess TaiMed Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TaiMed Biologics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TaiMed Biologics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
127%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TaiMed Biologics expected to grow at an attractive rate?
  • TaiMed Biologics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • TaiMed Biologics's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • TaiMed Biologics's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:4147 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:4147 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 127%
GTSM:4147 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 89.8%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4147 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4147 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 5,905 3,296 1
2020-12-31 2,241 -229 423 3
2019-12-31 793 -804 -459 3
2019-11-11
GTSM:4147 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 611 -459 -650
2019-06-30 486 -489 -684
2019-03-31 369 -498 -539
2018-12-31 241 -523 -322
2018-09-30 128 -530 -335
2018-06-30 43 -523 -83
2018-03-31 7 -552 -316
2017-12-31 8 -516 -525
2017-09-30 7 -403 -466
2017-06-30 5 -223 -410
2017-03-31 3 -241 -307
2016-12-31 2 -172 -282

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TaiMed Biologics's earnings are expected to grow significantly at over 20% yearly.
  • TaiMed Biologics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4147 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from TaiMed Biologics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4147 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 13.07 13.07 13.07 1.00
2020-12-31 1.68 2.54 1.24 3.00
2019-12-31 -1.82 -1.56 -2.01 3.00
2019-11-11
GTSM:4147 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 -2.59
2019-06-30 -2.72
2019-03-31 -2.15
2018-12-31 -1.28
2018-09-30 -1.34
2018-06-30 -0.33
2018-03-31 -1.26
2017-12-31 -2.10
2017-09-30 -1.86
2017-06-30 -1.64
2017-03-31 -1.23
2016-12-31 -1.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • TaiMed Biologics is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess TaiMed Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TaiMed Biologics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TaiMed Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TaiMed Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TaiMed Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TaiMed Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TaiMed Biologics's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TaiMed Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TaiMed Biologics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4147 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 610.60 -650.10 40.97 588.58
2019-06-30 486.30 -683.98 43.28 396.52
2019-03-31 369.38 -539.38 42.32 440.62
2018-12-31 241.04 -321.71 42.63 440.39
2018-09-30 128.45 -335.18 47.94 486.35
2018-06-30 43.23 -82.91 43.97 475.15
2018-03-31 7.22 -316.08 43.94 525.62
2017-12-31 8.44 -524.55 42.92 510.74
2017-09-30 6.65 -465.89 41.02 449.27
2017-06-30 4.87 -410.02 38.67 400.09
2017-03-31 3.09 -307.16 38.62 283.73
2016-12-31 2.08 -281.96 38.37 276.61
2016-09-30 1.45 -285.00 52.47 264.85
2016-06-30 0.83 -423.37 52.74 396.59
2016-03-31 0.21 -465.46 51.07 438.72
2015-12-31 -471.68 48.68 442.46
2015-09-30 -441.22 34.38 426.87
2015-06-30 -333.12 32.38 322.41
2015-03-31 -273.04 30.35 260.05
2014-12-31 -281.74 45.73 249.83
2014-09-30 -284.82 43.41 249.59
2014-06-30 -289.47 43.01 253.43
2014-03-31 -280.39 41.35 243.57
2013-12-31 -251.68 24.41 233.05
2013-09-30 -224.68 23.11 206.90
2013-06-30 -197.68 21.81 180.74
2013-03-31 -182.76 21.64 182.09
2012-12-31 -167.84 21.46 183.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TaiMed Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TaiMed Biologics has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TaiMed Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TaiMed Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TaiMed Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TaiMed Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TaiMed Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TaiMed Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TaiMed Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TaiMed Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • TaiMed Biologics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TaiMed Biologics Company Filings, last reported 1 month ago.

GTSM:4147 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 3,664.01 0.00 1,672.01
2019-06-30 3,982.05 0.00 1,894.46
2019-03-31 4,057.18 0.00 1,935.98
2018-12-31 4,080.49 0.00 2,009.49
2018-09-30 4,208.30 0.00 2,366.22
2018-06-30 4,539.84 0.00 2,645.13
2018-03-31 4,416.89 0.00 3,448.34
2017-12-31 4,292.25 0.00 3,629.33
2017-09-30 4,460.78 0.00 4,000.50
2017-06-30 4,568.55 0.00 4,270.21
2017-03-31 4,676.49 0.00 4,319.06
2016-12-31 4,713.79 0.00 4,410.32
2016-09-30 4,797.79 0.00 4,468.35
2016-06-30 4,820.18 0.00 4,480.32
2016-03-31 4,868.28 0.00 4,531.55
2015-12-31 4,899.81 0.00 4,530.20
2015-09-30 1,513.74 0.00 1,268.17
2015-06-30 1,677.83 0.00 1,371.08
2015-03-31 1,782.99 0.00 1,429.28
2014-12-31 1,830.35 0.00 1,497.56
2014-09-30
2014-06-30 1,973.73 0.00 1,612.68
2014-03-31 657.73 0.00 338.13
2013-12-31 657.73 0.00 338.13
2013-09-30 657.73 0.00 338.13
2013-06-30 814.45 0.00 451.45
2013-03-31 814.45 0.00 451.45
2012-12-31 883.93 0.00 509.27
  • TaiMed Biologics has no debt.
  • TaiMed Biologics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TaiMed Biologics has sufficient cash runway for 2 years based on current free cash flow.
  • TaiMed Biologics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 48.9% each year.
X
Financial health checks
We assess TaiMed Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TaiMed Biologics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TaiMed Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TaiMed Biologics dividends. Estimated to be 0.74% next year.
If you bought NT$2,000 of TaiMed Biologics shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TaiMed Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TaiMed Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4147 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4147 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 3.01 2.00
2020-12-31 0.04 2.00
2019-12-31 0.00 2.00
2019-11-11

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TaiMed Biologics has not reported any payouts.
  • Unable to verify if TaiMed Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TaiMed Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TaiMed Biologics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of TaiMed Biologics's dividends in 3 years as they are not expected to pay a notable one for Taiwan, Province of China.
X
Income/ dividend checks
We assess TaiMed Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TaiMed Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TaiMed Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TaiMed Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Chang
CEO Bio

James Chang, Ph.D serves as the Chief Executive Officer, President and Director of TaiMed Biologics, Inc. James Chang served as Senior Director of Allergan Pharmaceuticals, Irvine, CA. James Chang holds PH.D. of Chemical Engineering, University of Washington, Seattle.

CEO Compensation
  • Insufficient data for James to compare compensation growth.
  • Insufficient data for James to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

James Chang

TITLE
CEO, President & Director

David Ho

TITLE
Scientific Co-Founder

Ing-Wen Tsai

TITLE
Co-Founder

Lan-Bo Chen

TITLE
Co-Founder

Jack Chen

TITLE
Chief Financial Officer
TENURE
3.8 yrs

Chang Chin-Ming

TITLE
Chief Technology Officer
TENURE
1.8 yrs

Hui Fang Zheng

TITLE
Head of Audit Department
Board of Directors Tenure

Average tenure of the TaiMed Biologics board of directors in years:

0.8
Average Tenure
  • The average tenure for the TaiMed Biologics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Lu-Ping Chow

TITLE
Chairman of the Board
TENURE
1.8 yrs

James Chang

TITLE
CEO, President & Director

Ta-mon Tseng

TITLE
Director
AGE
61
TENURE
0.8 yrs

Frank Chen

TITLE
Director
AGE
61

Lung-Yeh Cho

TITLE
Director

Der-Zen Liu

TITLE
Director
TENURE
0.8 yrs

Hsiao-Ling Shen

TITLE
Supervisor

Grace Lee

TITLE
Supervisor

Edward Lin

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess TaiMed Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TaiMed Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company develops and markets TMB-355, a humanized monoclonal antibody intravenous infusion for the treatment of HIV-1 infection. It is also developing TMB-355, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trial for treating HIV/AIDS; TMB-607, a novel HIV-1 protease inhibitor that is in Phase I clinical trial; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trial for treating HIV infections; TMB-Bispecific, a bispecific neutralizing antibody that is in Phase I clinical trial to treat HIV infections; and TMB-ADC, an antibody–drug conjugate for treating HIV infection. The company was founded in 2007 and is based in Taipei City, Taiwan.

Details
Name: TaiMed Biologics Inc.
4147
Exchange: GTSM
Founded: 2007
NT$34,674,337,500
252,177,000
Website: http://www.taimedbiologics.com
Address: TaiMed Biologics Inc.
No. 607, Ruiguang Road,
3rd Floor,
Taipei City,
11492,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4147 Common Stock Taipei Exchange TW TWD 28. Jun 2010
Number of employees
Current staff
Staff numbers
0
TaiMed Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 14:58
End of day share price update: 2019/11/11 00:00
Last estimates confirmation: 2019/10/01
Last earnings filing: 2019/11/07
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.